Back to News
Market Impact: 0.4
LEO Pharma Announces FDA Acceptance of Dersimelagon NDA with Priority Review and Closes Acquisition from Tanabe Pharma
Source: Business Wire
Healthcare & BiotechM&A & RestructuringRegulation & Legislation
LEO Pharma said the FDA accepted its New Drug Application for dersimelagon and granted Priority Review, accelerating the regulatory review timeline for the treatment. The company also completed its acquisition from Tanabe Pharma, adding a strategic corporate-development milestone alongside the potential product catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers
- India forces caller-ID apps to feed spam reports to telcos
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal